Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
about
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsNew directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunityCurrent and emerging strategies for the prevention of graft-versus-host diseaseOutcomes from unrelated donor hematopoietic stem cell transplantationLow incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouHematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia.Current and future approaches for control of graft-versus-host disease.Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment.Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationThe effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.Current issues in chronic graft-versus-host disease.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrPathogenesis and management of graft-versus-host disease.Less graft-versus-host disease after rabbit antithymocyte globulin conditioning in unrelated bone marrow transplantation for leukemia and myelodysplasia: comparison with matched related bone marrow transplantationT-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCTLow-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.How we treat chronic graft-versus-host disease.Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemiaGraft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantationWho is fit for allogeneic transplantation?Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation.New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies.Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancyInfluence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapyOutcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamideAntilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects.Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups.Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders.Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantationHigher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.
P2860
Q24200813-BEF3715F-C4F7-4F43-A233-61578D1B2F8DQ26823090-3A0F0291-7E28-49CB-AF0A-F2577A39F2CAQ27016541-19D275B5-14CB-41F9-B678-920C7C43151BQ27027854-5BD25D2C-63F5-4F44-BFA0-46DD940176FDQ30252205-320BED1B-6583-4C30-9C4D-424755390B38Q31143348-A38C638D-A118-4CC9-B9C3-DEDAA6CA5D3EQ33363625-8B2D6F65-1047-4544-B106-A1C60F0FE91EQ33376254-BDC0422C-2067-48C8-B1A7-A0C144062F6CQ33642625-6C0078B4-F1AE-4CCB-86C9-7B996B63993CQ33652103-B79DC5DC-6B3C-4A27-83BC-73BA901F59E8Q33685495-73F26CC2-A833-45B9-B11E-874797502107Q33749684-A3D02266-5FBC-4B7C-84BE-C410EEF6EA71Q33764825-349AD1F2-1B06-494A-B8C1-1D8D8CF8FC16Q33797194-596188D4-E29A-4BBD-AC8F-56D1DED77AC0Q33917187-F175EEDE-2300-42BA-B18C-707EE1B1D502Q34044024-5A64DC49-D696-46C8-9C8D-41D7577E9C7EQ34077479-8BAAA5A5-FEAB-4430-9413-107C1B429BA9Q34134601-E370A7AE-DEE6-485C-BCAD-5B12E2C191BDQ34398411-EDD883FF-16A8-4181-A036-C88FAEF2FB6FQ34860077-23EFEDF1-6459-44D3-A130-4B17DA9CACDAQ35004923-9574E364-A4C6-4522-9377-1B511183CFD6Q35083281-943399C2-E215-411B-809D-932D63ED3C5DQ35317371-D961DDDF-093E-4D93-B950-8F430102E7A7Q35321329-12ECE7BC-EC50-48F8-9526-7FFE9773C663Q35499395-CBCC7E4E-C633-4AE9-9043-A6D416ABFF8BQ35561803-EBE8FD8A-299E-4C9A-8468-B14A069A9C76Q35574785-6AC45C2D-57F9-4868-970F-81F90DAD70FFQ35660739-3A85445C-F3F1-4E7B-A8CB-AC1689FA8D5FQ35670693-8C7DDF71-F66E-49E4-93F1-30710A75E2F9Q35688840-E41990D3-0202-4F89-9A3D-7CACB6ACBCB4Q35809873-81084F6C-73C2-4AAC-A2F6-346D52B383A8Q35848407-66F9F65C-C9A0-4D59-B4E7-F003EFFB26FCQ35849011-93D5DE73-3072-4603-A791-563DA6B6983FQ35877266-D2598C7C-0430-41A8-9B82-C15972E8379FQ35959473-E1530FE6-25C0-4937-86F6-EDE3E0111263Q36133000-D338392A-CD6B-42D3-B950-BDBFD681AE52Q36305355-575E98CC-2B97-4819-8BFE-68DF028F0D7FQ36416597-9AEAC758-20FE-40BF-B448-2F146AB64E30Q36570651-745B74DE-AD1C-4884-A006-C2CD451764BCQ36592428-AE4081D1-948F-4938-9213-008730FB18CD
P2860
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@ast
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@en
Antithymocyte globulin for gra ...... aliano Trapianti Midollo Osseo
@nl
type
label
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@ast
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@en
Antithymocyte globulin for gra ...... aliano Trapianti Midollo Osseo
@nl
prefLabel
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@ast
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@en
Antithymocyte globulin for gra ...... aliano Trapianti Midollo Osseo
@nl
P2093
P1433
P1476
Antithymocyte globulin for gra ...... apianti Midollo Osseo (GITMO).
@en
P2093
Alessandrino PE
Bacigalupo A
Barbanti M
Lamparelli T
P304
P356
10.1182/BLOOD.V98.10.2942
P407
P577
2001-11-01T00:00:00Z